Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells

Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells

Specific cancer cell vulnerabilities can provide an opportunity for the development of novel cancer therapeutics. In this study the authors demonstrate that targeting ADAR1 represents a potential therapeutic vulnerability in cancers with activated interferon response signatures.

Guardado en:
Detalles Bibliográficos
Autores principales: Hugh S. Gannon, Tao Zou, Michael K. Kiessling, Galen F. Gao, Diana Cai, Peter S. Choi, Alexandru P. Ivan, Ilana Buchumenski, Ashton C. Berger, Jonathan T. Goldstein, Andrew D. Cherniack, Francisca Vazquez, Aviad Tsherniak, Erez Y. Levanon, William C. Hahn, Matthew Meyerson
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/101c1efd608349f2b4bd50157c1c3989
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Specific cancer cell vulnerabilities can provide an opportunity for the development of novel cancer therapeutics. In this study the authors demonstrate that targeting ADAR1 represents a potential therapeutic vulnerability in cancers with activated interferon response signatures.

Ejemplares similares